



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :  A61K 9/10, 47/00, 47/26, 47/12, 47/44, 47/10	A1	(11) International Publication Number: WO 00/38652  (43) International Publication Date: 6 July 2000 (06.07.00)
(21) International Application Number: PCT/US99/30527		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 20 December 1999 (20.12.99)		
(30) Priority Data: 09/221,181 23 December 1998 (23.12.98) US 09/448,205 23 November 1999 (23.11.99) US		
(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).		
(72) Inventors: GOLDENBERG, Merrill, Seymour; 3616 Radcliffe Road, Thousand Oaks, CA 91360 (US). SHAN, Daxian; Apartment 534, 1382 E. Hillcrest Drive, Thousand Oaks, CA 91360 (US). BEEKMAN, Alice, C.; Apartment 184, 300 Rolling Oaks Drive, Thousand Oaks, CA 91360 (US).		
(74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).		

(54) Title: POLYOL/OIL SUSPENSIONS FOR THE SUSTAINED RELEASE OF PROTEINS

## (57) Abstract

The present invention relates to the preparation of polyol/thickened oil suspensions containing a biologically active agent, for the sustained delivery of the biologically active agent. The described protein/glycerol/oil suspensions show sustained release of protein, e.g., G-CSF, of up to at least one week.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

POLYOL/OIL SUSPENSIONS FOR THE SUSTAINED  
RELEASE OF PROTEINS

CROSS REFERENCE TO RELATED APPLICATIONS

5

This application is a continuation in part of U.S. patent application serial no. 09/221,181 filed December 23, 1998 which is incorporated by reference herein.

10

FIELD OF THE INVENTION

The present invention relates to the preparation of polyol/thickened oil suspensions containing a biologically active agent, for the sustained delivery of the biologically active agent.

BACKGROUND OF THE INVENTION

20 Due to recent advances in genetic and cell engineering technologies, proteins known to exhibit various pharmacological actions *in vivo* are capable of being produced in large amounts for pharmaceutical applications. Such pharmaceutical proteins include 25 erythropoietin (EPO), novel erythropoiesis stimulating protein (NESP), granulocyte colony-stimulating factor (G-CSF), interferons (alpha, beta, gamma, consensus), tumor necrosis factor binding protein (TNFbp), interleukin-1 receptor antagonist (IL-1ra), brain-30 derived neurotrophic factor (BDNF), keratinocyte growth factor (KGF), stem cell factor (SCF), megakaryocyte growth differentiation factor (MGDF),

- 2 -

osteoprotegerin (OPG), glial cell line derived neurotrophic factor (GDNF), somatotrophins and obesity protein (OB protein). OB protein may also be referred to herein as leptin.

5        Many illnesses or conditions treated with pharmaceutical proteins require sustained protein levels to achieve the most effective therapeutic result. However, as with most protein pharmaceuticals, the generally short biological half-life requires  
10      frequent administration. These repeated injections are given at various intervals which result in fluctuating medication levels at a significant physical and monetary burden on the patients. Since many conditions respond better to controlled levels of a  
15      pharmaceutical, a need exists for controlled release of a medicament to provide longer periods of consistent release. Such sustained-release medicaments would provide a means of controlling blood levels of the active ingredient, thus providing the patient with  
20      enhanced prophylactic, therapeutic or diagnostic effects, as well as greater safety, patient convenience and patient compliance. Also such sustained release compositions can lead to dose sparing and thus lower cost of protein production. Unfortunately, the  
25      instability of most proteins (e.g. denaturation and loss of bioactivity upon exposure to heat, organic solvents, etc.) has greatly limited the development and evaluation of sustained-release formulations.

Attempts to develop sustained-release  
30      formulations have included the use of a variety of biodegradable and non-biodegradable polymer (e.g. poly(lactide-co-glycolide)) microparticles containing the active ingredient (see e.g., Wise et al.,

- 3 -

*Contraception*, 8:227-234 (1973); and Hutchinson et al., *Biochem. Soc. Trans.*, 13:520-523 (1985)), and a variety of techniques are known by which active agents, e.g. proteins, can be incorporated into polymeric

5 microspheres (see e.g., U.S. Patent No. 4,675,189 and references cited therein). Unfortunately, some of the sustained release devices utilizing microparticles still suffer from such things as: low entrapment efficiency; active agent aggregation formation; high

10 initial bursts of active agent with minimal release thereafter; and incomplete release of active agent.

Other drug-loaded polymeric devices have also been investigated for long term, therapeutic treatment of various diseases, again with much attention being

15 directed to polymers derived from alpha hydroxycarboxylic acids, especially lactic acid in both its racemic and optically active form, and glycolic acid, and copolymers thereof. These polymers are commercially available and have been utilized in

20 FDA-approved systems, e.g., the Lupron Depot™, which consists of injectable microparticles which release leuprolide acetate for about 30 days for the treatment of prostate cancer.

Various problems identified with the use of

25 such polymers include: inability of certain macromolecules to diffuse out through the matrix; deterioration and decomposition of the drug (e.g., denaturation caused by the use of organic solvents); irritation to the organism (e.g. side effects due to

30 use of organic solvents); low biodegradability (such as that which occurs with polycondensation of a polymer with a multifunctional alcohol or multifunctional

- 4 -

carboxylic acid, i.e., ointments); and slow rates of degradation.

A variety of oil based formulations have been described. Welch in U.S. Patent No. 2,491,537 discloses the use of oil suspensions (gelled vegetable oil) to provide 24 hour release of penicillin. Buckwalter in U.S. Patent No. 2,507,193 discloses release in rabbits for up to eleven days using procaine penicillin suspended in peanut oil gelled with 5% aluminum monostearate (AIMS). Anschel in U.S. Patent No. 2,964,448 discloses suspensions of relaxin in a vegetable oil gelled with AIMS. Anschel reports 5-7 days of relaxation and discloses longer effect (up to 23 days) by heat treating the suspension containing AIMS. Yamahira et al. in U.S. Patent No. 4,855,134 disclose sustained-release preparations of indomethacin or interferon in admixture with a pharmaceutically acceptable biodegradable carrier, e.g., gelatin. Mitchell in U.S. 5,411,951 discloses compositions wherein metal-associated somatotropin is present in a biocompatible oil and it is demonstrated that the compositions can be parenterally administered for prolonged release of somatotropin in animals. Ferguson et al. in U.S. 4,977,140 disclose sustained release formulations comprising bovine somatotropin, a wax, and an oil. Reichert et al. in WO 96/18417 disclose pharmaceutical compositions comprising mixtures of crystalline G-CSF and vegetable oils.

There have also been a number of reports discussing efforts to develop drug delivery systems utilizing protein that are subject to aggregation. For example, Grodsky et al., U.S. Patent No. 4,371,523, describe the use of anti-aggregation agents, e.g.,

- 5 -

glutamic acid and/or aspartic acid, to develop insulin formulations. Blackshear et al., U.S. Patent 4,439,181, describe mixing glycerol or another polyol with an aqueous protein hormone solution prior to the 5 introduction of the solution into the drug delivery system. Wigness et al., PCT Publication WO 85/02118 describe the use of glycerol to prevent precipitation of proteins within drug delivery systems; and Azain et al., EP Publication 0 374 120 A2 describe stable 10 somatotropin compositions which utilize, *inter alia*, a stabilizing polyol.

Despite the advances made in the processes described above, there is still a need to develop pharmaceutical formulations which achieve a more 15 versatile and effective means of sustained-release for clinical applications. Numerous recombinant or natural proteins could benefit from constant long term release and thereby provide more effective clinical results.

Human recombinant G-CSF selectively 20 stimulates neutrophils, a type of white blood cell used for fighting infection. Currently, Filgrastim®, a recombinant G-CSF, is available for therapeutic use. The structure of G-CSF under various conditions has been extensively studied; Lu et al., *J. Biol. Chem.* 25 Vol. 267, 8770-8777 (1992).

G-CSF is labile and highly susceptible to environmental factors such as temperature, humidity, oxygen and ultraviolet rays. And, because of its hydrophobic characteristics, G-CSF is difficult to 30 formulate due to formation of dimer and higher order aggregates (macro range) during long-term storage. G-CSF has been shown to be very prone to aggregation, especially at neutral pH, elevated salt and

- 6 -

temperatures (i.e. physiological serum conditions). This instability makes the sustained release (of a period of one week or greater) by conventional delivery systems very problematic, and in fact, such systems  
5 generally provide only a few days of release at best.

It is an object of the present invention to produce a G-CSF-containing preparation which would provide for the sustained release of G-CSF. Production of such preparations is achieved using glycerol/oil  
10 suspensions containing G-CSF, and, importantly, pharmaceutical compositions using these G-CSF/glycerol/oil suspensions are capable of providing increased bioavailability, protein protection, decreased degradation and slow release with increased  
15 protein stability and potency. Importantly, pharmaceutical compositions of the present invention provide a simple, rapid and inexpensive means of controlled recombinant protein release for effective prophylactic, therapeutic or diagnostic results.

20

#### SUMMARY OF THE INVENTION

The present invention thus relates to the preparation of a stabilized, prolonged-release  
25 injectable suspension containing a biologically active agent. The present invention stems from the observation that G-CSF powder is stabilized when suspended in glycerol and remains stabilized when the suspension is further suspended in a thickened oil such as sesame oil containing a low percentage of aluminum monostearate, or wax, thus providing a stabilized, prolonged-release injectable preparation. Importantly,

the methods described herein are broadly applicable to other proteins (or analogs thereof), as well as G-CSF.

In one embodiment, the present invention provides pharmaceutical compositions comprising an effective amount of a biologically active agent (BAA) incorporated into a polyol/thickened oil suspension, said biologically active agent in the form of a powder or aqueous solution, and said suspension capable of providing for the sustained-release of the biologically active agent.

In another embodiment, the present invention provides a method for the parenteral administration of a BAA/glycerol/oil suspension to a warm blooded animal, wherein said suspension is administered subcutaneously, or intramuscularly and the biologically active agent is released from the suspension at a controlled rate for up to one week or more.

The present invention further relates to processes for preparing sustained-release injectable pharmaceutical compositions of BAA/polyol/oil suspensions as above. The principal embodiment comprises: (a) suspending a BAA in a polyol to form a BAA/polyol suspension; and (b) suspending said BAA/polyol suspension in a mixture comprising a thickened oil, or wax, to form a BAA/polyol/oil suspension.

The present invention further relates to a prefilled syringe comprising said formulation.

The present invention also relates to methods of treatment of individuals using the stabilized, prolonged-release injectable preparations described herein.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following terms shall have the following meaning:

5 "Biodegradable" is defined as meaning that the polyol/oil vehicle will erode or degrade or absorb or metabolize *in vivo* to form smaller non-toxic components.

10 "Biocompatible" is defined as meaning the oil and its thickeners and other excipients will have no intolerable adverse effect on the polypeptide, or human being treated.

15 "Parenteral administration" is defined as meaning any route of administration other than the alimentary canal, including, for example, subcutaneous, intramuscular, intrathecal, intraorbital, intraarticular, pulmonary, nasal, rectal and otic.

20 As used herein, biologically active agents refers to recombinant or naturally occurring proteins, whether human or animal, useful for prophylactic, therapeutic or diagnostic application. The biologically active agent can be natural, synthetic, semi-synthetic or derivatives thereof. In addition, biologically active agents of the present invention can 25 be PEGylated or conjugated with water soluble adducts such as carbohydrates, e.g., dextran. A wide range of biologically active agents are contemplated. These include but are not limited to hormones, cytokines, hematopoietic factors, growth factors, antiobesity factors, trophic factors, anti-inflammatory factors, and enzymes (see also U.S. Patent No. 4,695,463 for additional examples of useful biologically active agents). One skilled in the art will readily be able

- 9 -

to adapt a desired biologically active agent to the compositions of present invention which can also include small organic or organometallic compounds.

Such proteins would include but are not limited to granulocyte-colony stimulating factors (G-CSF's) (see, U.S. Patent Nos. 4,810,643, 4,999,291, 5,581,476, 5,582,823, and PCT Publication No. 94/17185, hereby incorporated by reference including drawings), interferons (see, U.S. Patent Nos. 5,372,808, 5,541,293 10 4,897,471, and 4,695,623 hereby incorporated by reference including drawings), interleukins (see, U.S. Patent No. 5,075,222, hereby incorporated by reference including drawings), erythropoietins (see, U.S. Patent Nos. 4,703,008, 5,441,868, 5,618,698 5,547,933, and 15 5,621,080 hereby incorporated by reference including drawings), stem cell factor (PCT Publication Nos. 91/05795, 92/17505 and 95/17206, hereby incorporated by reference including drawings), osteoprotegerin (PCT Publication No. 97/23614, hereby incorporated by reference including drawings), novel erythropoiesis 20 stimulating protein (NESP) (PCT Publication No. 94/09257, hereby incorporated by reference including drawings) and leptin (OB protein).

Provided below is a working example using G-CSF, which, as described above, is a therapeutic protein used to treat hematopoietic disorders. In general, G-CSF useful in the practice of this invention may be a form isolated from mammalian organisms or, alternatively, a product of chemical synthetic procedures or of prokaryotic or eukaryotic host expression of exogenous DNA sequences obtained by genomic or cDNA cloning or by DNA synthesis. Suitable prokaryotic hosts include various bacteria (e.g.,

*E. coli*); suitable eukaryotic hosts include yeast (e.g., *S. cerevisiae*) and mammalian cells (e.g., Chinese hamster ovary cells, monkey cells). Depending upon the host employed, the G-CSF expression product 5 may be glycosylated with mammalian or other eukaryotic carbohydrates, or it may be non-glycosylated. The G-CSF expression product may also include an initial methionine amino acid residue (at position -1). The present invention contemplates the use of any and all 10 such forms of G-CSF, although recombinant G-CSF, especially *E. coli* derived, is preferred, for, among other things, greatest commercial practicality.

Certain G-CSF analogs have been reported to be biologically functional, and these may also be 15 chemically modified, by, for example, the addition of one or more polyethylene glycol molecules. G-CSF analogs are reported in U.S. Patent No. 4,810,643. Examples of other G-CSF analogs which have been 20 reported to have biological activity are those set forth in AU-A-76380/91, EP O 459 630, EP O 272 703, EP O 473 268 and EP O 335 423, although no representation is made with regard to the activity of each analog reportedly disclosed. See also 25 AU-A-10948/92, PCT 94/00913 and EP O 243 153. Of course, if one so desires when treating non-human mammals, one may use recombinant non-human G-CSF's, such as recombinant murine, bovine, canine, etc. See PCT WO 9105798 and PCT WO 8910932, for example.

The type of G-CSF used for the present 30 preparations may be selected from those described in PCT Publication No. 94/17185, as cited above and herein incorporated by reference in its entirety. The 174 amino acid sequence for mature, recombinant methionyl

- 11 -

human G-CSF is presented herein as SEQ ID NO: 1, where the first amino acid of the mature protein is threonine (T) (at position 1) and a methionyl residue is located at position -1 (not included in the sequence below).

5

SEQ ID NO: 1

10

	T	P	L	G	P	A	S	S	L	P	Q	S	F	L	
	L	K	C	L	E	Q	V	R	K	I	Q	G	D	G	A
	A	L	Q	E	K	L	C	A	T	Y	K	L	C	H	P
	E	E	L	V	L	L	G	H	S	L	G	I	P	W	A
15	P	L	S	S	C	P	S	Q	A	L	Q	L	A	G	C
	L	S	Q	L	H	S	G	L	F	L	Y	Q	G	L	L
	Q	A	L	E	G	I	S	P	E	L	G	P	T	L	D
	T	L	Q	L	D	V	A	D	F	A	T	T	I	W	Q
	Q	M	E	E	L	G	M	A	P	A	L	Q	P	T	Q
20	G	A	M	P	A	F	A	S	A	F	Q	R	R	A	G
	G	V	L	V	A	S	H	L	Q	S	F	L	E	V	S
	Y	R	V	L	R	H	L	A	Q	P					

However, as with any of the present G-CSF moieties, the  
25 methionyl residue at position -1 may be absent.

Also included are those proteins as set forth above with amino acid substitutions which are "conservative" according to acidity, charge, hydrophobicity, polarity, size or any other characteristic known to those skilled in the art.

These are set forth in Table 1, below. See generally, Creighton, *Proteins, passim* (W.H. Freeman and Company, N.Y., 1984); Ford et al., *Protein Expression and Purification* 2:95-107 (1991), which are herein incorporated by reference.

10

Table 1

Conservative Amino Acid Substitutions

Basic:	arginine lysine histidine
Acidic:	glutamic acid aspartic acid
Polar:	glutamine asparagine
Hydrophobic:	leucine isoleucine valine
Aromatic:	phenylalanine tryptophan tyrosine
Small:	glycine alanine serine threonine methionine

In addition, biologically active agents can also include but are not limited to insulin, gastrin, 15 prolactin, adrenocorticotrophic hormone (ACTH), thyroid

stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), motilin, interferons (alpha, beta, gamma), interleukins (IL-1 to IL-12), tumor necrosis factor (TNF), tumor necrosis factor-binding protein (TNF-bp), brain derived neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), neurotrophic factor 3 (NT3), fibroblast growth factors (FGF), neurotrophic growth factor (NGF), insulin-like growth factors (IGFs), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), megakaryocyte derived growth factor (MGDF), keratinocyte growth factor (KGF), thrombopoietin, platelet-derived growth factor (PGDF), colony simulating growth factors (CSFs), bone morphogenic protein (BMP), superoxide dismutase (SOD), tissue plasminogen activator (TPA), urokinase, somatotropins, streptokinase and kallikrein. The term proteins, as used herein, includes peptides, polypeptides, consensus molecules, analogs, derivatives or combinations thereof.

The BAA used to prepare the sustained-release compositions of the present invention can be in solution or powder form and is first admixed with a polyol, e.g., glycerol. The BAA can be in the form of a powder in glycerol or dissolved or suspended in an aqueous solution of glycerol. The polyol is added in an amount sufficient to stabilize (e.g., prevent aggregation) of the BAA during long-term storage of the BAA in the suspension.

Other biocompatible C-4 to C-19 polyols contemplated for use include, but are not limited to, C-4: erythritol; C-5: arabinose, xylose, ribose;

- 14 -

C-6: inositol, fructose, galactose, glucose, mannose; C-12: maltose and sucrose. If the polyol used is in solid form, it will be first prepared as an aqueous or aqueous organic solution or fluidized by means of heat 5 or pressure, and admixed with the BAA. The level of polyol used can preferably range from 5%-90%, more preferably from 10%-50%, and most preferably from 10%-30% by weight. In a preferred embodiment wherein G-CSF is the biologically active agent and glycerol is 10 the polyol, 20% aqueous glycerol is used. In other preferred embodiments, where little or no water is present, 20% glycerol is with respect to the total volume of the formulation.

The oils used in the present invention are 15 biocompatible, of low acidity and essentially free from rancidity. Such oils are selected from the group consisting of, for example, sesame seed, canola, saffron, castor, cottonseed, olive, peanut, sunflower seed, ethyl oleate, vitamin E including  $\alpha$ -tocopherol 20 and its derivatives, and Miglyol 812.

The glycerol/oil suspensions will also contain a "thickener" or "gelling agent" which serves to retard hydration of the suspension, give the body of oil greater viscosity or viscoelasticity, and thereby 25 decrease the rate of release of the BAA from the suspension following administration and also increase the stabilization of the BAA, and increase the physical stability of the suspension as a whole (i.e., prevent phase separation). Such agents include polyvalent 30 metal salts of organic acids, e.g., aluminum, zinc, magnesium or calcium salts of lauric acid, palmitic acid, stearic acid and the like, and oleaginous materials such as waxes and high viscosity oils and

- 15 -

organic or inorganic fillers such as polymers and salts. Aluminum monostearate and distearate and white wax are particularly preferred agents. Said agents are usually present at concentrations (based on weight of oil) of between about 0.1% and about 99%, more typically between about 0.5% and about 90% and for metal salts even more typically 0.5% to 20%. This ratio is important for purposes of assuring that the agent doesn't increase the viscosity of the suspension to the point where the suspension is no longer useful for injection through a syringe. For highly viscous formulations, implants are also contemplated.

The glycerol/oil suspensions may further comprise surface active agents or emulsifiers to stabilize the glycerol/oil suspension and prevent it from separating. This surface active agent or emulsifier can be ionic or nonionic and may be selected from the group consisting of, for example, Span 40, Span 80, Pluronics®, and egg lecithin, or mixtures thereof, preferably with a HLB (hydrophile-lipophile balance) of 1-10, more preferably 2-8, and even more preferably 4-8. The surfactant can also help dissipate the oil in the biological environment. The surfactant is usually present at 0.1% to 50%, preferably 0.2% to 20%, and more preferably 0.5% to 10% by weight of oil. Certain materials, such as hydrogenated vegetable oil can function as both a thickener and stabilizer of the glycerol suspension.

The BAA/glycerol/oil suspensions of the present invention can be prepared by suspending a biologically active agent (in powdered form) in substantially pure glycerol solution to form a BAA/glycerol suspension, and then suspending said

BAA/glycerol suspension in a solution comprising oil alone or oil containing a "gelling agent" suspended or dissolved in the oil. The oil (containing gelling agent) may first need to be heated (with mixing) to

5 assure that the gelling agent completely dissolves in the oil. The BAA formulation can also be prepared by dissolving or suspending the BAA in aqueous glycerol solution (preferably containing a surfactant) and mixing the solution into an oil (preferably containing

10 a surfactant), and where aqueous glycerol is preferably buffered at a stable pH (e.g., acidic for G-CSF). The aqueous phase preferably contains a moderate to high HLB and the oil phase preferably contains a low HLB surfactant. In the present invention, moderate to high

15 HLB is greater than about 8, and low HLB is lower than about 8.

In general, comprehended by the invention are pharmaceutical compositions comprising effective amounts of biologically active agent, or derivative products (e.g., precipitates), together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, anti-oxidants (e.g., ascorbic acid and Vitamin E), adjuvants and/or carriers needed for administration. (See PCT 97/01331 hereby incorporated by reference.) The optimal pharmaceutical formulation for a desired biologically active agent will be determined by one skilled in the art depending upon the route of administration, desired dosage and duration of release. Exemplary pharmaceutical compositions are disclosed in Remington's Pharmaceutical Sciences (Mack Publishing Co., 18th Ed., Easton, PA, pgs. 1435-1712 (1990)). The pharmaceutical compositions of the present invention are particularly

- 17 -

attractive for parenteral administration, e.g., by injection intramuscularly, subcutaneously, or intraperitoneally.

Therapeutic uses of the compositions of the  
5 present invention depend on the biologically active agent used. One skilled in the art will readily be able to adapt a desired biologically active agent to the present invention for its intended therapeutic uses. Therapeutic uses for such agents are set forth  
10 in greater detail in the following publications hereby incorporated by reference including drawings.

Therapeutic uses include but are not limited to uses for proteins like granulocyte-colony stimulating factors (see, U.S. Patent Nos. 4,999,291, 5,581,476, 15 5,582,823, 4,810,643 and PCT Publication No. 94/17185, hereby incorporated by reference including drawings), interferons (see, U.S. Patent Nos. 5,372,808, 5,541,293, hereby incorporated by reference including drawings), interleukins (see, U.S. Patent No. 20 5,075,222, hereby incorporated by reference including drawings), erythropoietins (see, U.S. Patent Nos. 4,703,008, 5,441,868, 5,618,698 5,547,933, and 5,621,080 hereby incorporated by reference including drawings), stem cell factor (PCT Publication Nos. 25 91/05795, 92/17505 and 95/17206, hereby incorporated by reference including drawings), OB protein (see PCT publication Nos. 96/40912, 96/05309, 97/00128, 97/01010 and 97/06816 hereby incorporated by reference including figures), novel erythropoiesis stimulating 30 protein (PCT Publication No. 94/09257, hereby incorporated by reference including drawings), and small molecule drugs. In addition, the present compositions may also be used for manufacture of one or

more medicaments for treatment or amelioration of the conditions the biologically active agent is intended to treat.

As specifically relates to G-CSF, the therapeutic has been shown to be effective in treating inflammatory bowel disease. For example, it has been reported that an adolescent boy with Crohn's disease and enterocutaneous fistulas had a response to treatment with G-CSF (filgrastim) after all standard treatments failed; Vaughn and Drumm, *New England Journal of Medicine*, 340(3):239-240 (1999). It has also been reported that prolonged high-dose therapy with G-CSF may have anti-inflammatory effects in colitis; Hommes et al., *Clin Exp. Immunol.*, 106:529-533 (1996). It is thus envisioned that the G-CSF-containing suspensions of the present invention will also be effective in treatment of inflammatory bowel diseases.

One skilled in the art will be able to ascertain effective dosages by administration and observing the desired therapeutic effect. Preferably, for G-CSF, the formulation of the suspension will be such that between about 0.01 µg G-CSF moiety/kg body weight/day and 10 mg G-CSF moiety/kg body weight/day will yield the desired therapeutic effect. The effective dosages may be determined using diagnostic tools over time. For example, a diagnostic for measuring the amount of G-CSF in the blood (or plasma or serum) may first be used to determine endogenous levels of G-CSF protein. Such diagnostic tool may be in the form of an antibody assay, such as an antibody sandwich assay. The amount of endogenous G-CSF protein is quantified initially, and a baseline is determined.

- 19 -

The therapeutic dosages are determined as the quantification of endogenous and exogenous G-CSF protein moiety (that is, protein, analog or derivative found within the body, either self-produced or 5 administered) is continued over the course of therapy. The dosages may therefore vary over the course of therapy, with, for example, a relatively high dosage being used initially, until therapeutic benefit is seen, and lower dosages used to maintain the 10 therapeutic benefits. Alternatively, the levels of neutrophils are determined and monitored over the course of the therapy. The dosage is adjusted to maintain the required level of neutrophil counts with the lowest frequency of injections.

15 The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof.

#### EXAMPLE 1

20

This example describes the preparation of G-CSF powder by spray-drying.

G-CSF solution (~2.75 mg/ml, with 5% sorbitol, in 0.58mM HCl) was placed in dialysis tubing 25 (Spectrum Lab Inc., flat width 18 ± 2 mm, diameter 11.5 mm, 1.0 ml/cm), and dialyzed against water (pH 3.25) at 4°C for 24 hours. During the dialysis, the water is changed four times. Dialyzed G-CSF solution (~1100 ml) was then placed in an ultrafiltration cell 30 and air pressure applied on the solution. After two hours, about 300 ml of concentrated G-CSF solution was collected and filtered through a 0.2 mm filter unit. The concentration of the final G-CSF solution is

- 20 -

9.134 mg/ml. The spray-drying was performed on a BUCHI 190 Mini Spray Dryer (Brinkmann Institute), and all of the glassware of the spray dryer was first washed with deionized water, followed by sterile water, followed by 5 ethanol. The spray-drying was performed with inlet air flow of 450 normal liters/hour, and the feed rate of G-CSF solution was 1.0 ml/min. G-CSF powder (2.640 grams, 82.7% G-CSF) was obtained from the 290 mL starting G-CSF solution.

10

EXAMPLE 2

This example describes the preparation of G-CSF/glycerol suspensions and the use of the 15 G-CSF/glycerol suspensions to prepare G-CSF/glycerol/oil formulations.

Step 1. A G-CSF/glycerol suspension was first prepared by placing 105.4 milligrams G-CSF spray-dried powder (prepared as described in Example 1) and 20 2.401 mL glycerol in a mortar and grinding the mixture until no coarse particles were seen.

Step 2. A thickened oil suspension was then prepared by placing 45.67 grams sesame oil (Croda, Inc.) and 1.91 grams aluminum monostearate 25 (AIMS) (Fluka) in a 125 mL erlenmeyer flask and mixing with a magnetic stirrer at room temperature for 20 minutes, followed by heating at 165°C-170°C under nitrogen atmosphere with stirring. The stirring is continued for two hours, and the mixture then cooled to 30 room temperature, resulting in an opalescent gel-like thickened oil (3% AIMS).

Step 3. One mL G-CSF/glycerol suspension and 4 mL thickened oil were placed in a mortar and

- 21 -

ground together until well mixed. The suspension (G-CSF/20% glycerol/3% AIMS/oil) was stored in a sterile sample vial at 4°C until needed.

5

EXAMPLE 3

This example describes the preparation of a G-CSF/glycerol-containing viscous oil suspension further containing L-ascorbic acid and surfactant.

10       L-Ascorbic acid (50 mg) was dissolved in a 1 mL glycerol solution by heating and stirring the mixture. After being cooled to room temperature, the ascorbic acid/glycerol solution was mixed with GCSF powder (45.3 mg) and Span 80 (250 mL).

15       3.75 mL thickened oil (3% AIMS) prepared as described above was added to the G-CSF/ascorbic acid/glycerol mixture and ground together to give a viscous oil suspension (G-CSF/20% glycerol+ascorbic acid/Span 80/3% AIMS/oil).

20

EXAMPLE 4

This example shows the preparation of an oil thickened with 7% white wax.

25       The thickened 7% wax/oil was produced (using the procedure described in Example 2, Step 2) by heating a mixture of white wax (4.49 grams) and sesame oil (59.65 grams) at 160°C under nitrogen atmosphere for 2 hours.

30

EXAMPLE 5

This example shows the preparation of various G-CSF-containing oil formulations using 7% wax as  
5 thickener and with different glycerol levels.

Preparation 1: G-CSF powder (27.6 mg) and glycerol (600  $\mu$ L) were mixed in a mortar and ground until no observable coarse particles were seen. Then 2.4 mL of the thickened 7% wax/oil prepared as  
10 described in Example 4 was added to the GCSF/glycerol suspension. The mixture was ground together with mortar and pestle to give a viscous oil formulation (G-CSF/20% glycerol/7% wax).

Preparation 2: GCSF powder (45.3 mg) was  
15 mixed with 1.00 ml of ascorbic acid/glycerol solution (prepared as described in Example 3), and then 4.0 mL of thickened 7% wax/oil was added. The resulting mixture was ground together to give a viscous oil formulation (G-CSF/20% glycerol+ascorbic acid/7% wax).

20 Preparation 3: G-CSF powder (27.3 mg) and glycerol (450  $\mu$ L) were mixed in a mortar and ground until no observable coarse particles were seen. Then 2.55 mL of the thickened 7% wax/oil prepared as described in Example 4 was added to the GCSF/glycerol  
25 suspension. The mixture was ground together with mortar and pestle to give a viscous oil formulation (G-CSF/15% glycerol/7% wax).

Preparation 4: G-CSF powder (27.5 mg) and glycerol (750  $\mu$ L) were mixed in a mortar and ground  
30 until no observable coarse particles were seen. Then 2.25 mL of the thickened 7% wax/oil prepared as described in Example 4 was added to the GCSF/glycerol suspension. The mixture was ground together with

- 23 -

mortar and pestle to give a viscous oil formulation (G-CSF/25% glycerol/7% wax).

EXAMPLE 6

5

This example shows the preparation of an G-CSF/glycerol oil thickened with 10% white wax.

The thickened 10% wax/oil was produced (using the procedure described in Example 2, Step 2) by  
10 heating a mixture of white wax (6.5 grams) and sesame oil (58.5 grams) at 160°C under nitrogen atmosphere for 2 hours.

GCSF powder (27.4 mg) and glycerol (600 µl) were mixed together, and then 2.40 mL of thickened oil  
15 (10% wax) was added to the GCSF/glycerol suspension. The mixture was ground to give a viscous oil formulation (G-CSF/20% glycerol/10% wax).

EXAMPLE 7

20

This example describes the *in vivo* testing of the suspensions prepared in Examples 2-6.

Splenectomized mice (BDF1) were injected once (subcutaneously) with 30 mg/kg of the various  
25 G-CSF-containing suspensions, and the various controls. The mice had their blood analyzed over several days. G-CSF powder (- glycerol) in 3% AIMS oil (30 mg/Kg); G-CSF powder dissolved in water (30 mg/Kg); and 1X PBS were run as  
30 controls. The data is summarized in Table 1 below.

- 24 -

Table 1

	<u>Formulation</u>	<u>Neutrophil Count (<math>10^6/\text{mL}</math>)</u>		
		<u>Day 3</u>	<u>Day 5</u>	<u>Day 7</u>
5	1X PBS	2.0	2.0	2.0
	G-CSF in pH 3.25 water (+ 5% sorbitol)	2.0	2.0	2.0
10	G-CSF in glycerol	3.5	2.0	2.0
	G-CSF (- glycerol) in 3% AIMS/oil	1.5	1.5	1.5
15	G-CSF/20% glycerol 3% AIMS/oil	24	33	19
	G-CSF/20% glycerol ascorbic acid/Span 80 3% AIMS/oil	18.1	23.8	8.7
20	G-CSF/20% glycerol 7% wax/oil	27	40.2	10.3
25	G-CSF/15% glycerol 7% wax/oil	32.4	36	8.1
	G-CSF/25% glycerol 7% wax/oil	24.6	38.2	13.9
30	G-CSF/20% glycerol 10% wax/oil	33.6	56.9	25.6

As evidenced by the data in Table 1, the  
 35 polyol/thickened oil suspensions are capable of  
 providing for the sustained release of G-CSF for  
 periods of at least one week. Importantly, it should  
 be noted that G-CSF could not be delivered in the oils  
 without the addition of the polyol.

40

EXAMPLE 8

This example shows the preparation of an oils thickened with glycerin stearate.

45 Preparation 1: Glycerol tristearate (1.00 gram), glycerol monostearate (4.00 grams), and sesame oil (45.00 grams) were placed in a bottle and heated at 160°C under nitrogen atmosphere for 2 hours. The

- 25 -

mixture was then cooled to room temperature while being vortexed. A white thickened oil was obtained.

Preparation 2: Glycerol monostearate (0.80 grams) and sesame oil (9.20 grams) were placed in a 5 bottle and heated at 160°C under nitrogen atmosphere for 2 hours. The mixture was then cooled to room temperature while being vortexed. A white thickened oil was obtained.

10

EXAMPLE 9

This example describes the preparation of thick oil using a mixture of sesame oil and the more viscous hydrogenated vegetable oil.

15 Sesame oil (6.00 mL) and hydrogenated vegetable oil (34.00 mL) were placed in a bottle and the mixture heated at 160°C under nitrogen atmosphere for 2 hours. After the mixture cooled to room temperature, a thickened oil was obtained.

20

EXAMPLE 10

This example shows the preparation of G-CSF/glycerol in oil suspensions where the oil 25 contains a mixture of sesame and hydrogenated vegetable oil and where the hydrogenated vegetable oil thickens the mixture.

Preparation 1: GCSF powder (10.0 mg) and glycerol (0.20 mL) were mixed, and then an oil mixture 30 (hydrogenated oil/sesame oil = 5/3, 0.80 mL) was added. The mixture was ground together with a mortar and pestle to give a viscous suspension formulation. This

- 26 -

formulation was filled into a syringe and was  
syringable.

Preparation 2: GCSF powder (10.3 mg) and  
glycerol (0.20 mL) were mixed, and then an oil mixture  
5 (hydrogenated oil/sesame oil = 3/17, 0.8 mL)) was  
added. The mixture was ground together with a mortar  
and pestle to give a viscous suspension formulation.  
This formulation was filled into a syringe and was  
syringable.

10

EXAMPLE 11

This example shows the preparation of a  
thickened oils using stearic acid, stearyl alcohol, and  
15 combinations thereof, as thickeners  $\pm$  G-CSF/glycerol.

Preparation 1: Stearic acid (1.00 gram) and  
sesame oil (9.00 grams) were placed in a bottle and the  
mixture heated at 160°C under nitrogen atmosphere for 2  
hours. After cooling to room temperature with shaking  
20 the mixture became a viscous thickened oil.

Preparation 2: Stearyl alcohol (1.00 gram)  
and sesame oil (9.00 grams) were placed in a bottle and  
the mixture heated at 160°C under a nitrogen atmosphere  
for 2 hours. After cooling to room temperature with  
25 shaking the mixture became a viscous thickened oil.

Preparation 3: Stearyl alcohol (0.50 grams),  
stearic acid (0.50 grams), and sesame oil (9.00 grams)  
are placed in a bottle and the mixture heated at 160°C  
under nitrogen atmosphere for 2 hours. After cooling  
30 to room temperature with shaking the mixture became a  
viscous thickened oil.

Preparation 4: G-CSF powder (9.8 mg) and  
glycerol (0.20 mL) were mixed and then 0.80 mL of

- 27 -

thickened oil (10% stearyl alcohol) was added. The mixture was ground for 10 minutes to give an oil formulation which was filled into a 1 mL syringe and was syringable.

5 Preparation 5: G-CSF powder (10.3 mg) and glycerol (0.20 mL) were mixed and then 0.80 mL of thickened oil (10% thickener, stearyl alcohol/stearic acid = 3/1) was added. The mixture was ground for 10 minutes to give an oil formulation which was filled  
10 into a 1 mL syringe and was syringable.

#### EXAMPLE 12

This example shows the preparation of G-CSF  
15 containing aqueous glycerol in oil emulsion formulations where the G-CSF is mixed in the aqueous glycerol phase.

The water phase consisted of 12.7 mg/mL G-CSF, 50% glycerol, 1%(w/v) Pluronic F68, 10 mM acetate (pH 4.0) and 0.44 mM HCl. A mixture of 1% Pluronic L101 in corn oil formed the oil phase. A 50:50 and 70:30 mixture of the two phases were homogenized with a Virtis Handishear homogenizer for 45 seconds to form the respective emulsion  
25 formulations.

#### EXAMPLE 13

This example is prepared in a similar manner  
30 to Example 2 except the G-CSF dose is approximately 10 mg/Kg. After a single injection the neutrophils were elevated for at least one week.

What is claimed is:

1. A pharmaceutical composition comprising an effective amount of a biologically active agent (BAA) incorporated into a biocompatible polyol/oil suspension, wherein said suspension contains a thickener.
2. The composition of Claim 1 wherein said biocompatible polyol is selected from the group consisting of glycerol, erythritol, arabinose, xylose, ribose, inositol, fructose, galactose, maltose, and sucrose.
3. The composition of Claim 1 wherein the thickener is selected from the group consisting of polyvalent metal salts of organic acids, oleaginous materials such as waxes and high viscosity oils, and organic or inorganic fillers such as polymers and salts.
4. The composition of Claim 3 wherein the thickener is aluminum monostearate.
5. The composition of Claim 3 wherein the thickener is white wax.
6. The composition of Claim 1 wherein said oil is selected from the group consisting of sesame, castor, cottonseed, canola, saffron, olive, peanut, sunflower seed,  $\alpha$ -tocopherol, and ethyl oleate.
7. The composition of claim 1, wherein said biologically active agent is a protein selected from

the group consisting of interferon consensus,  
erythropoietin, granulocyte-colony stimulating factor  
(GCSF), stem cell factor (SCF), leptin (OB protein),  
tumor necrosis factor-binding protein (TNF-bp),  
5 interleukin-1 receptor antagonist (IL-1ra), brain  
derived neurotrophic factor (BDNF), glial derived  
neurotrophic factor (GDNF), neurotrophic factor 3  
(NT3), osteoprotegerin (OPG), granulocyte macrophage  
colony stimulating factor (GM-CSF), megakaryocyte  
10 derived growth factor (MGDF), keratinocyte growth  
factor (KGF), thrombopoietin, and novel erythropoiesis  
stimulating protein (NESP).

8. The composition of claim 1, wherein said  
15 biologically active agent is a small molecule drug.

9. A process for preparing pharmaceutical  
compositions of BAA/polyol/oil sustained-release  
suspensions which comprises:  
20 (a) suspending a BAA in a polyol to form  
a BAA/polyol mixture;  
                 (b) suspending said BAA/polyol mixture  
in a mixture comprising a thickened oil to form a  
BAA/polyol/oil suspension.

25  
10. A method for the parenteral  
administration of a BAA/polyol/oil suspension to a warm  
blooded animal, wherein said suspension is administered  
subcutaneously, or intramuscularly and the biologically  
30 active agent is released from the suspension at a  
controlled rate for up to one week or more.

- 30 -

11. A prefilled syringe containing the pharmaceutical composition of Claim 1.

12. A pharmaceutical composition comprising  
5 an effective amount of a biologically active agent (BAA) incorporated into a biocompatible polyol/oil suspension, wherein said suspension contains a thickener; said composition capable of providing for the sustained-release of the biologically active agent.

## SEQUENCE LISTING

<110> AMGEN INC.

<120> POLYOL/OIL SUSPENSIONS FOR SUSTAINED RELEASE OF PROTEINS

<130> A-576

<140> NOT ASSIGNED YET

<141> 1998-12-23

<160> 1

<170> PatentIn Ver. 2.0

<210> 1

<211> 174

<212> PRT

<213> granulocyte colony-stimulating factor

<400> 1

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys  
1 5 10 15

Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln  
20 25 30

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val  
35 40 45

Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys  
50 55 60

Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser  
65 70 75 80

Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser  
85 90 95

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp  
100 105 110

Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro  
115 120 125

Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe  
130 135 140

Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe  
145 150 155 160

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
165 170

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30527

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/10 A61K47/00 A61K47/26 A61K47/12 A61K47/44  
A61K47/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 389 177 A (BEECHAM GROUP PLC) 26 September 1990 (1990-09-26) page 2, line 48 - line 52 page 3, line 9 - line 11 page 3, line 15 - line 18; claim 1; examples 2,3	1,8,12
Y	WO 96 18417 A (SCHERING CORP) 20 June 1996 (1996-06-20) cited in the application page 5, line 3 - line 6 page 4, line 35 -page 5, line 3; claims 21-23,32-34; example 41 ---	1-6,10, 12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 May 2000

Date of mailing of the international search report

31/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30527

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 85 02118 A (UNIV MINNESOTA) 23 May 1985 (1985-05-23) cited in the application page 4, line 10 - line 19 page 10, line 19 -page 11, line 1; claims 1-6; examples 1,2 ----	1-6,10, 12
A	US 5 411 951 A (MITCHELL JAMES W) 2 May 1995 (1995-05-02) cited in the application column 3, line 48 - line 55 column 4, line 59 - line 65 column 6, line 17 - line 50; claims 1-16; examples 2-4 ----	1-12
A	EP 0 374 120 A (MONSANTO CO) 20 June 1990 (1990-06-20) cited in the application page 3, line 53 - last line; claims 1,14; examples 1-7 -----	1-12

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/30527

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of Invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Interr. /nal Application No

PCT/US 99/30527

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0389177 A	26-09-1990	US 5114929 A AU 626649 B AU 5147690 A CA 2012492 A JP 2300115 A NZ 232979 A PT 93497 A ZA 9002089 A	19-05-1992 06-08-1992 27-09-1990 21-09-1990 12-12-1990 26-05-1992 07-11-1990 27-03-1991
WO 9618417 A	20-06-1996	US 6004549 A AU 4413296 A	21-12-1999 03-07-1996
WO 8502118 A	23-05-1985	CA 1252717 A DE 3482657 D DK 330985 A EP 0164397 A JP 61500439 T	18-04-1989 09-08-1990 19-07-1985 18-12-1985 13-03-1986
US 5411951 A	02-05-1995	US 5013713 A AT 62598 T AT 132372 T AU 601272 B AU 1439088 A AU 573904 B AU 4823785 A BG 47039 A CA 1309018 A CN 1007124 B CN 1044761 A, B CS 8507118 A CZ 8708156 A DD 244914 A DE 3582548 D DE 3588074 D DK 449585 A EP 0177478 A EP 0343696 A ES 547489 D ES 8702440 A GR 852398 A HU 38839 A, B IE 65392 B IL 76554 A JP 2082550 C JP 7045409 B JP 61091130 A KR 8902631 B LV 5186 A NO 173975 C NO 930531 A NZ 213701 A PL 255622 A PT 81248 B PT 81248 A SU 1595330 A US 4985404 A, B US 5595971 A US 5086041 A	07-05-1991 15-05-1991 15-01-1996 06-09-1990 29-09-1988 23-06-1988 10-04-1986 16-04-1990 20-10-1992 14-03-1990 22-08-1990 12-11-1987 16-09-1998 22-04-1987 23-05-1991 15-02-1996 05-04-1986 09-04-1986 29-11-1989 16-12-1986 16-03-1987 03-02-1986 28-07-1986 18-10-1995 29-04-1990 23-08-1996 17-05-1995 09-05-1986 21-07-1989 10-10-1993 02-03-1994 07-04-1986 30-08-1988 30-12-1986 20-10-1987 01-08-1988 23-09-1990 15-01-1991 21-01-1997 04-02-1992

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/30527

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5411951 A		US 5739108 A		14-04-1998
		US 5474980 A		12-12-1995
		YU 158485 A		31-12-1988
		ZA 8507642 A		27-08-1986
EP 0374120 A	20-06-1990	AU 4617689 A		21-06-1990
		BR 8906435 A		28-08-1990
		CA 2005226 A		13-06-1990
		CN 1043631 A		11-07-1990
		CZ 8907028 A		18-01-1995
		DK 626089 A		14-06-1990
		HU 52395 A		28-07-1990
		JP 2204418 A		14-08-1990
		KR 9205660 B		13-07-1992
		NZ 231730 A		25-10-1991
		PT 92548 A		29-06-1990
		ZA 8909476 A		31-07-1991